152 related articles for article (PubMed ID: 26998164)
1. Effect of CD38 on the multidrug resistance of human chronic myelogenous leukemia K562 cells to doxorubicin.
Yalçintepe L; Halis E; Ulku S
Oncol Lett; 2016 Mar; 11(3):2290-2296. PubMed ID: 26998164
[TBL] [Abstract][Full Text] [Related]
2. Reversal of P-glycoprotein-mediated multidrug resistance by guggulsterone in doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells.
Xu HB; Li L; Liu GQ
Pharmazie; 2009 Oct; 64(10):660-5. PubMed ID: 19947169
[TBL] [Abstract][Full Text] [Related]
3. Targeting P-glycoprotein expression and cancer cell energy metabolism: combination of metformin and 2-deoxyglucose reverses the multidrug resistance of K562/Dox cells to doxorubicin.
Xue C; Wang C; Liu Q; Meng Q; Sun H; Huo X; Ma X; Liu Z; Ma X; Peng J; Liu K
Tumour Biol; 2016 Jul; 37(7):8587-97. PubMed ID: 26733176
[TBL] [Abstract][Full Text] [Related]
4. HOXB4 knockdown reverses multidrug resistance of human myelogenous leukemia K562/ADM cells by downregulating P-gp, MRP1 and BCRP expression via PI3K/Akt signaling pathway.
Wang H; Jia XH; Chen JR; Yi YJ; Wang JY; Li YJ; Xie SY
Int J Oncol; 2016 Dec; 49(6):2529-2537. PubMed ID: 27779650
[TBL] [Abstract][Full Text] [Related]
5. Reversal of p-glycoprotein-mediated multidrug resistance by CJX1, an amlodipine derivative, in doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells.
Ji BS; He L; Liu GQ
Life Sci; 2005 Sep; 77(18):2221-32. PubMed ID: 15967469
[TBL] [Abstract][Full Text] [Related]
6. Differential effects of peroxisome proliferator-activated receptor agonists on doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells.
Yousefi B; Samadi N; Baradaran B; Rameshknia V; Shafiei-Irannejad V; Majidinia M; Targhaze N; Zarghami N
Cell Mol Biol (Noisy-le-grand); 2015 Dec; 61(8):118-22. PubMed ID: 26718439
[TBL] [Abstract][Full Text] [Related]
7. Timosaponin A-III reverses multi-drug resistance in human chronic myelogenous leukemia K562/ADM cells via downregulation of MDR1 and MRP1 expression by inhibiting PI3K/Akt signaling pathway.
Chen JR; Jia XH; Wang H; Yi YJ; Wang JY; Li YJ
Int J Oncol; 2016 May; 48(5):2063-70. PubMed ID: 26984633
[TBL] [Abstract][Full Text] [Related]
8. Balaglitazone reverses P-glycoprotein-mediated multidrug resistance via upregulation of PTEN in a PPARγ-dependent manner in leukemia cells.
Yousefi B; Azimi A; Majidinia M; Shafiei-Irannejad V; Badalzadeh R; Baradaran B; Zarghami N; Samadi N
Tumour Biol; 2017 Oct; 39(10):1010428317716501. PubMed ID: 28978268
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of tensin homolog deleted on chromosome ten (PTEN) by ciglitazone sensitizes doxorubicin-resistance leukemia cancer cells to treatment.
Mashayekhi S; Yousefi B; Tohidi E; Darband SG; Mirza-Aghazadeh-Attari M; Sadighparvar S; Kaviani M; Shafiei-Irannejad V; Kafil HS; Karimian A; Jadidi-Niaragh F; Majidinia M
J Cell Biochem; 2019 Sep; 120(9):15719-15729. PubMed ID: 31087712
[TBL] [Abstract][Full Text] [Related]
10. The synergistic reversal effect of multidrug resistance by quercetin and hyperthermia in doxorubicin-resistant human myelogenous leukemia cells.
Shen J; Zhang W; Wu J; Zhu Y
Int J Hyperthermia; 2008 Mar; 24(2):151-9. PubMed ID: 18283591
[TBL] [Abstract][Full Text] [Related]
11. Reversal of P-glycoprotein mediated multidrug resistance in K562 cell line by a novel synthetic calmodulin inhibitor, E6.
Zhu HJ; Wang JS; Guo QL; Jiang Y; Liu GQ
Biol Pharm Bull; 2005 Oct; 28(10):1974-8. PubMed ID: 16204958
[TBL] [Abstract][Full Text] [Related]
12. Coformulation of doxorubicin and curcumin in poly(D,L-lactide-co-glycolide) nanoparticles suppresses the development of multidrug resistance in K562 cells.
Misra R; Sahoo SK
Mol Pharm; 2011 Jun; 8(3):852-66. PubMed ID: 21480667
[TBL] [Abstract][Full Text] [Related]
13. Germacrone reverses adriamycin resistance in human chronic myelogenous leukemia K562/ADM cells by suppressing MDR1 gene/P-glycoprotein expression.
Pan J; Miao D; Chen L
Chem Biol Interact; 2018 May; 288():32-37. PubMed ID: 29655913
[TBL] [Abstract][Full Text] [Related]
14. TRIB2 knockdown as a regulator of chemotherapy resistance and proliferation via the ERK/STAT3 signaling pathway in human chronic myelogenous leukemia K562/ADM cells.
Ma X; Zhou X; Qu H; Ma Y; Yue Z; Shang W; Wang P; Xie S; Li Y; Sun Y
Oncol Rep; 2018 Apr; 39(4):1910-1918. PubMed ID: 29436678
[TBL] [Abstract][Full Text] [Related]
15. Curcumin increases the sensitivity of K562/DOX cells to doxorubicin by targeting S100 calcium-binding protein A8 and P-glycoprotein.
Yang L; Li D; Tang P; Zuo Y
Oncol Lett; 2020 Jan; 19(1):83-92. PubMed ID: 31897118
[TBL] [Abstract][Full Text] [Related]
16. P-glycoprotein antibody functionalized carbon nanotube overcomes the multidrug resistance of human leukemia cells.
Li R; Wu R; Zhao L; Wu M; Yang L; Zou H
ACS Nano; 2010 Mar; 4(3):1399-408. PubMed ID: 20148593
[TBL] [Abstract][Full Text] [Related]
17. Sequential gene expression of P-glycoprotein (P-gp), multidrug resistance-associated protein (MRP) and lung resistance protein: functional activity of P-gp and MRP present in the doxorubicin-resistant human K562 cell lines.
Grandjean F; Brémaud L; Verdier M; Robert J; Ratinaud MH
Anticancer Drugs; 2001 Mar; 12(3):247-58. PubMed ID: 11290872
[TBL] [Abstract][Full Text] [Related]
18. CJY, an isoflavone, reverses P-glycoprotein-mediated multidrug-resistance in doxorubicin-resistant human myelogenous leukaemia (K562/DOX) cells.
Ji BS; He L
J Pharm Pharmacol; 2007 Jul; 59(7):1011-5. PubMed ID: 17637197
[TBL] [Abstract][Full Text] [Related]
19. BME, a novel compound of anthraquinone, down regulated P-glycoprotein expression in doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells via generation of reactive oxygen species.
Wang J; Liu L; Cen J; Ji B
Chem Biol Interact; 2015 Sep; 239():139-45. PubMed ID: 26169035
[TBL] [Abstract][Full Text] [Related]
20. Sensitization of multidrug-resistant malignant cells by liposomes co-encapsulating doxorubicin and chloroquine through autophagic inhibition.
Gao M; Xu Y; Qiu L
J Liposome Res; 2017 Jun; 27(2):151-160. PubMed ID: 27250110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]